ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer’s Trial

Posted: July 29, 2024 at 2:33 am

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer’s disease patients

Read the rest here:
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Related Posts